2014
Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis
Lima I, Oliveira R, Cabral M, Atta A, Marchi S, Reis E, Reis M, Barbosa L, Santiago M. Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis. Rheumatology International 2014, 34: 1231-1234. PMID: 24719228, DOI: 10.1007/s00296-014-3009-z.Peer-Reviewed Original ResearchConceptsAnti-neutrophil cytoplasmic antibodiesAnti-PR3 antibodiesIndirect immunofluorescencePresence of ANCAPrevalence of ANCAInfectious diseasesComponents of neutrophilsGroup of patientsAnti-MPO antibodiesSera of patientsChest X-rayAnti-PR3Cytoplasmic antibodiesVasculitic syndromesTB patientsPulmonary tuberculosisAutoimmune disordersPresent studyClinical similaritiesSuch antibodiesPatientsELISA kitTuberculosisAntibodiesAutoantibodies
2009
Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil.
Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, Reis M, Arruda S, Riley L. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. The International Journal Of Tuberculosis And Lung Disease 2009, 13: 719-25. PMID: 19460247.Peer-Reviewed Original ResearchConceptsHousehold contactsLatent tuberculosis infectionLTBI treatmentLatent tuberculosis infection treatmentTB-endemic countriesRisks of treatmentHigh-risk populationPulmonary TBMedication intoleranceTuberculosis infectionTuberculosis controlRisk factorsHigh riskSide effectsInfection treatmentHospitalVisitsMonthsTreatmentFollowINHRiskTBRegimenPatients